Steven DuBois, MD, MS

Steven DuBois, MD, MS

Pediatric Hematology/Oncology

Contact Information

Fax

617-632-5710

Appointments

888-733-4662 (New Pediatric Patients)
617-632-3270 (Established Pediatric Patients)

Biography

Steven DuBois, MD, MS

Dr. DuBois is director of experimental therapeutics at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. He is a pediatric oncologist with an active clinical and translational research program focused on patients with advanced neuroblastoma and Ewing sarcoma. He conducts phase 1 and 2 clinical trials of novel targeted agents. His clinical practice focuses on providing outstanding team-based care for children and young adults with solid cancers. He is also a member of the American Pediatric Society.

Researcher

Physician

Director, Experimental Therapeutics
Senior Physician
Associate Professor of Pediatrics, Harvard Medical School

Centers/Programs

Pediatric Liver Tumor Program

Clinical Interests

Ewing sarcoma, Neuroblastoma, Novel agents, Other pediatric solid tumors, Phase 1 clinical trials

Board Certification

  • Pediatric Hematology/Oncology, 2009

Fellowship

  • Boston Children's Hospital/Dana-Farber Cancer Institute, Pediatric Hematology/Oncology

Residency

  • University of California, San Francisco School of Medicine, Pediatrics

Medical School

  • University of California, San Francisco School of Medicine

Recent Awards

  • Dana-Farber Cancer Institute Clinical Innovation Award, 2020

Research

    Dr. DuBois is director of experimental therapeutics at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. He is a pediatric oncologist with an active clinical and translational research program focused on patients with advanced neuroblastoma and Ewing sarcoma. He conducts phase 1 and 2 clinical trials of novel targeted agents.

    Research Departments

    Publications

      • Phase 1 study of cabozantinib in combination with topotecan-cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcoma. Pediatr Blood Cancer. 2023 Sep 16; e30681. View in: Pubmed

      • Long-Term Outcomes in Patients With Localized Ewing Sarcoma Treated With Interval-Compressed Chemotherapy on Children's Oncology Group Study AEWS0031. J Clin Oncol. 2023 Aug 31; JCO2300053. View in: Pubmed

      • Evaluation of prevalence and outcomes of serial tyrosine kinase inhibitor use in pediatric patients with advanced solid tumors. Pediatr Blood Cancer. 2023 Nov; 70(11):e30652. View in: Pubmed

      • Clinical development of new drugs for adults and children with cancer, 2010-2020. J Natl Cancer Inst. 2023 08 08; 115(8):917-925. View in: Pubmed

      • Children's Oncology Group's 2023 blueprint for research: Bone tumors. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30583. View in: Pubmed

      • Children's Oncology Group's 2023 blueprint for research: Neuroblastoma. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30572. View in: Pubmed

      • Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma. Cancer Med. 2023 07; 12(14):15207-15216. View in: Pubmed

      • A single-institution pediatric and young adult interventional oncology collaborative: Novel therapeutic options for relapsed/refractory solid tumors. Cancer Med. 2023 06; 12(12):13300-13308. View in: Pubmed

      • Ewing Sarcoma Drug Therapy: Current Standard of Care and Emerging Agents. Paediatr Drugs. 2023 Jul; 25(4):389-397. View in: Pubmed

      • Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents. J Clin Oncol. 2023 06 20; 41(18):3408-3422. View in: Pubmed

      • Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. J Clin Oncol. 2023 05 01; 41(13):2382-2393. View in: Pubmed

      • Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group. J Clin Oncol. 2023 04 10; 41(11):2098-2107. View in: Pubmed

      • A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl). Eur J Cancer. 2023 04; 183:11-23. View in: Pubmed

      • Modulation of Radiation Biomarkers in a Randomized Phase II Study of 131I-MIBG With or Without Radiation Sensitizers for Relapsed or Refractory Neuroblastoma. Int J Radiat Oncol Biol Phys. 2023 04 01; 115(5):1115-1128. View in: Pubmed

      • Systematic review of clinical drug development activities for neuroblastoma from 2011 to 2020. Pediatr Blood Cancer. 2023 05; 70(5):e30106. View in: Pubmed

      • Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. JCO Precis Oncol. 2022 Nov; 6:e2200390. View in: Pubmed

      • Clinical and biological features prognostic of survival after relapse or progression of INRGSS stage MS pattern neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2023 02; 70(2):e30054. View in: Pubmed

      • Early Termination of Oncology Clinical Trials in the United States. Cancer Med. 2023 03; 12(5):5517-5525. View in: Pubmed

      • Analysis of Local Control Outcomes and Clinical Prognostic Factors in Localized Pelvic Ewing Sarcoma Patients Treated With Radiation Therapy: A Report From the Children's Oncology Group. Int J Radiat Oncol Biol Phys. 2023 02 01; 115(2):337-346. View in: Pubmed

      • Adverse prognostic impact of the loss of STAG2 protein expression in patients with newly diagnosed localised Ewing sarcoma: A report from the Children's Oncology Group. Br J Cancer. 2022 Dec; 127(12):2220-2226. View in: Pubmed

      • NUT Carcinoma in Children and Adolescents: The Expert European Standard Clinical Practice Harmonized Recommendations. J Pediatr Hematol Oncol. 2023 05 01; 45(4):165-173. View in: Pubmed

      • Reply to D.J. Benedetti et al. J Clin Oncol. 2023 01 20; 41(3):707. View in: Pubmed

      • An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. NPJ Precis Oncol. 2022 Sep 17; 6(1):65. View in: Pubmed

      • Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer. 2022 09; 173:71-90. View in: Pubmed

      • Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group. Eur J Cancer. 2022 Sep; 172:264-275. View in: Pubmed

      • Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022 08; 28(8):1581-1589. View in: Pubmed

      • Report of the First International Symposium on NUT Carcinoma. Clin Cancer Res. 2022 06 13; 28(12):2493-2505. View in: Pubmed

      • Gamma Secretase Inhibition for a Child With Metastatic Glomus Tumor and Activated NOTCH1. JCO Precis Oncol. 2022 06; 6:e2200099. View in: Pubmed

      • Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro Oncol. 2022 06 01; 24(6):997-1007. View in: Pubmed

      • Histologic characterization of paediatric mesenchymal neoplasms treated with kinase-targeted therapy. Histopathology. 2022 Aug; 81(2):215-227. View in: Pubmed

      • 68 Ga-DOTATATE PET and functional imaging in pediatric pheochromocytoma and paraganglioma. Pediatr Blood Cancer. 2022 08; 69(8):e29740. View in: Pubmed

      • High-Risk Ewing Sarcoma: It Is Time to Break the Ceiling. J Clin Oncol. 2022 07 20; 40(21):2288-2290. View in: Pubmed

      • High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-13. View in: Pubmed

      • ACCELERATE - Five years accelerating cancer drug development for children and adolescents. Eur J Cancer. 2022 05; 166:145-164. View in: Pubmed

      • Reply to J.-G. Wang et al. J Clin Oncol. 2022 05 01; 40(13):1507-1508. View in: Pubmed

      • Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2022 09; 69(9):e29616. View in: Pubmed

      • Peripheral Blood Transcript Signatures after Internal 131I-mIBG Therapy in Relapsed and Refractory Neuroblastoma Patients Identifies Early and Late Biomarkers of Internal 131I Exposures. Radiat Res. 2022 02 01; 197(2):101-112. View in: Pubmed

      • Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precis Oncol. 2021; 5. View in: Pubmed

      • Molecular Characterization of Inflammatory Tumors Facilitates Initiation of Effective Therapy. Pediatrics. 2021 12 01; 148(6). View in: Pubmed

      • Patterns of Translocation Testing in Patients Enrolling in a Cooperative Group Trial for Newly Diagnosed Metastatic Ewing Sarcoma. Arch Pathol Lab Med. 2021 12 01; 145(12):1564-1568. View in: Pubmed

      • Belzutifan, a Potent HIF2a Inhibitor, in the Pacak-Zhuang Syndrome. N Engl J Med. 2021 11 25; 385(22):2059-2065. View in: Pubmed

      • The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute. J Natl Cancer Inst. 2021 11 02; 113(11):1453-1459. View in: Pubmed

      • Anatomic patterns of relapse and progression following treatment with 131 I-MIBG in relapsed or refractory neuroblastoma. Pediatr Blood Cancer. 2022 02; 69(2):e29396. View in: Pubmed

      • Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report. J Clin Oncol. 2021 12 20; 39(36):4029-4038. View in: Pubmed

      • Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms. J Clin Oncol. 2021 12 01; 39(34):3822-3828. View in: Pubmed

      • Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration. Eur J Cancer. 2021 11; 157:198-213. View in: Pubmed

      • Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021 12; 68(12):e29333. View in: Pubmed

      • Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. J Clin Oncol. 2021 11 01; 39(31):3506-3514. View in: Pubmed

      • NUT Carcinoma Without Upfront Surgical Resection: A Case Report. J Pediatr Hematol Oncol. 2021 07 01; 43(5):e707-e710. View in: Pubmed

      • Improving Outcomes in Children With High-Risk Neuroblastoma: The Role of Randomized Trials. J Clin Oncol. 2021 08 10; 39(23):2525-2527. View in: Pubmed

      • Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors. Eur J Drug Metab Pharmacokinet. 2021 May; 46(3):343-352. View in: Pubmed

      • Ewing Sarcoma-Diagnosis, Treatment, Clinical Challenges and Future Perspectives. J Clin Med. 2021 Apr 14; 10(8). View in: Pubmed

      • Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. Cancer Med. 2021 Apr; 10(7):2310-2318. View in: Pubmed

      • Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. Transplant Cell Ther. 2021 06; 27(6):490.e1-490.e8. View in: Pubmed

      • Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE. Eur J Cancer. 2021 03; 146:115-124. View in: Pubmed

      • Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors. Cancer Chemother Pharmacol. 2021 05; 87(5):621-634. View in: Pubmed

      • Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors. Cancer Med. 2021 02; 10(3):843-856. View in: Pubmed

      • A case of metastatic adenocarcinoma of unknown primary in a pediatric patient: Opportunities for precision medicine. Pediatr Blood Cancer. 2021 04; 68(4):e28780. View in: Pubmed

      • Opportunities and Challenges in Drug Development for Pediatric Cancers. Cancer Discov. 2021 03; 11(3):545-559. View in: Pubmed

      • Derivation and validation of risk groups in patients with osteosarcoma utilizing regression tree analysis. Pediatr Blood Cancer. 2021 03; 68(3):e28834. View in: Pubmed

      • Stereotactic Body Radiation Therapy for Metastatic and Recurrent Solid Tumors in Children and Young Adults. Int J Radiat Oncol Biol Phys. 2021 04 01; 109(5):1396-1405. View in: Pubmed

      • Role of bone marrow biopsy for staging new patients with Ewing sarcoma: A systematic review. Pediatr Blood Cancer. 2021 02; 68(2):e28807. View in: Pubmed

      • Advances and Challenges in Pediatric and Childhood Cancers. Cancer Cell. 2020 10 12; 38(4):429-432. View in: Pubmed

      • Germline MUTYH Mutation in a Pediatric Cancer Survivor Developing a Secondary Malignancy. J Pediatr Hematol Oncol. 2020 10; 42(7):e647-e654. View in: Pubmed

      • Landscape of phase 1 clinical trials for minors with cancer in the United States. Pediatr Blood Cancer. 2020 11; 67(11):e28694. View in: Pubmed

      • The RACE to accelerate drug development for children with cancer. Lancet Child Adolesc Health. 2020 10; 4(10):714-716. View in: Pubmed

      • Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center. Cancer Med. 2020 09; 9(18):6658-6666. View in: Pubmed

      • Trends in conditional survival and predictors of late death in neuroblastoma. Pediatr Blood Cancer. 2020 10; 67(10):e28329. View in: Pubmed

      • The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. Pediatr Blood Cancer. 2020 10; 67(10):e28559. View in: Pubmed

      • Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. Eur J Cancer. 2020 09; 136:52-68. View in: Pubmed

      • Population pharmacokinetics-pharmacodynamics of sunitinib in pediatric patients with solid tumors. Cancer Chemother Pharmacol. 2020 08; 86(2):181-192. View in: Pubmed

      • Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study. J Clin Oncol. 2020 08 20; 38(24):2741-2752. View in: Pubmed

      • Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group. Eur J Cancer. 2020 07; 133:112-119. View in: Pubmed

      • How to address challenges and opportunities in pediatric cancer drug development? Expert Opin Drug Discov. 2020 08; 15(8):869-872. View in: Pubmed

      • Sponsorship of oncology clinical trials in the United States according to age of eligibility. Cancer Med. 2020 07; 9(13):4495-4500. View in: Pubmed

      • DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. Mod Pathol. 2020 10; 33(10):1910-1921. View in: Pubmed

      • The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers. Paediatr Drugs. 2020 Apr; 22(2):189-197. View in: Pubmed

      • Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers. Clin Cancer Res. 2020 06 15; 26(12):2882-2890. View in: Pubmed

      • Pediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancers. J Natl Cancer Inst. 2020 03 01; 112(3):224-228. View in: Pubmed

      • Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020 04; 21(4):531-540. View in: Pubmed

      • New approaches to therapeutic drug development for childhood cancers. Curr Opin Pediatr. 2020 02; 32(1):35-40. View in: Pubmed

      • Physiologically Based Pharmacokinetic Modeling and Simulation of Sunitinib in Pediatrics. AAPS J. 2020 01 23; 22(2):31. View in: Pubmed

      • Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. Clin Cancer Res. 2020 05 15; 26(10):2297-2307. View in: Pubmed

      • Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020 01; 21(1):121-133. View in: Pubmed

      • An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients. JNCI Cancer Spectr. 2020 Apr; 4(2):pkz094. View in: Pubmed

      • A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma. Thyroid. 2019 11; 29(11):1704-1707. View in: Pubmed

      • Differences in Genomic Profiles and Outcomes Between Thoracic and Adrenal Neuroblastoma. J Natl Cancer Inst. 2019 11 01; 111(11):1192-1201. View in: Pubmed

      • Author Correction: Reprogramming Escherichia coli for the production of prenylated indole diketopiperazine alkaloids. Sci Rep. 2019 Oct 15; 9(1):15009. View in: Pubmed

      • Second malignancies in patients treated for Ewing sarcoma: A systematic review. Pediatr Blood Cancer. 2019 11; 66(11):e27938. View in: Pubmed

      • Clinical Impact of Tumor Mutational Burden in Neuroblastoma. J Natl Cancer Inst. 2019 07 01; 111(7):695-699. View in: Pubmed

      • Reprogramming Escherichia coli for the production of prenylated indole diketopiperazine alkaloids. Sci Rep. 2019 06 25; 9(1):9208. View in: Pubmed

      • Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2019 08; 66(8):e27819. View in: Pubmed

      • Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force. F1000Res. 2019; 8. View in: Pubmed

      • Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). Eur J Cancer. 2019 05; 112:66-79. View in: Pubmed

      • Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. Br J Cancer. 2019 Apr; 120(8):869. View in: Pubmed

      • Expanding the Spectrum of Pediatric NTRK-rearranged Mesenchymal Tumors. Am J Surg Pathol. 2019 04; 43(4):435-445. View in: Pubmed

      • Timing of first-in-child trials of FDA-approved oncology drugs. Eur J Cancer. 2019 05; 112:49-56. View in: Pubmed

      • Ushering in the next generation of precision trials for pediatric cancer. Science. 2019 Mar 15; 363(6432):1175-1181. View in: Pubmed

      • Winning the RACE: Expanding pediatric cancer drug approvals. Pediatr Blood Cancer. 2019 08; 66(8):e27705. View in: Pubmed

      • Duality of purpose: Participant and parent understanding of the purpose of genomic tumor profiling research among children and young adults with solid tumors. JCO Precis Oncol. 2019; 3. View in: Pubmed

      • Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies. Pediatr Blood Cancer. 2019 05; 66(5):e27595. View in: Pubmed

      • Risk stratification by somatic mutation burden in Ewing sarcoma. Cancer. 2019 04 15; 125(8):1357-1364. View in: Pubmed

      • Neuroblastoma and Histone Demethylation. N Engl J Med. 2018 10 11; 379(15):1476-1477. View in: Pubmed

      • Genome-Informed Targeted Therapy for Osteosarcoma. Cancer Discov. 2019 01; 9(1):46-63. View in: Pubmed

      • The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. Cancer. 2018 11 01; 124(21):4241-4247. View in: Pubmed

      • Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. Br J Cancer. 2018 08; 119(5):615-621. View in: Pubmed

      • Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2018 12 15; 24(24):6142-6149. View in: Pubmed

      • Comparison of Epidemiology, Clinical Features, and Outcomes of Patients with Reported Ewing Sarcoma and PNET over 40 Years Justifies Current WHO Classification and Treatment Approaches. Sarcoma. 2018; 2018:1712964. View in: Pubmed

      • Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors. JCO Precis Oncol. 2018; 2018. View in: Pubmed

      • Age dependency of primary tumor sites and metastases in patients with Ewing sarcoma. Pediatr Blood Cancer. 2018 09; 65(9):e27251. View in: Pubmed

      • Dual HDAC and PI3K Inhibition Abrogates NF?B- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. Cancer Res. 2018 07 15; 78(14):4007-4021. View in: Pubmed

      • Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis. Oncotarget. 2018 Apr 06; 9(26):18607-18626. View in: Pubmed

      • Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatr Blood Cancer. 2018 07; 65(7):e27023. View in: Pubmed

      • Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol. 2018 05; 19(5):705-714. View in: Pubmed

      • Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018 02 22; 378(8):731-739. View in: Pubmed

      • Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol. 2018 03; 31(3):463-473. View in: Pubmed

      • Pediatric NUT-midline carcinoma: Therapeutic success employing a sarcoma based multimodal approach. Pediatr Hematol Oncol. 2017 May; 34(4):231-237. View in: Pubmed

      • Combination of clofarabine, cyclophosphamide, and etoposide for relapsed or refractory childhood and adolescent acute myeloid leukemia. Pediatr Hematol Oncol. 2017 May; 34(4):187-198. View in: Pubmed

      • Identification of Patients With Localized Ewing Sarcoma at Higher Risk for Local Failure: A Report From the Children's Oncology Group. Int J Radiat Oncol Biol Phys. 2017 12 01; 99(5):1286-1294. View in: Pubmed

      • Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Cancer. 2017 Nov 01; 123(21):4224-4235. View in: Pubmed

      • Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After 131I- Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma. Int J Radiat Oncol Biol Phys. 2017 10 01; 99(2):468-475. View in: Pubmed

      • Evaluation of the utility of 99m Tc-MDP bone scintigraphy versus MIBG scintigraphy and cross-sectional imaging for staging patients with neuroblastoma. Pediatr Blood Cancer. 2017 Nov; 64(11). View in: Pubmed

      • A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. Clin Cancer Res. 2017 May 15; 23(10):2433-2441. View in: Pubmed

      • MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2017 Nov; 64(11). View in: Pubmed

      • Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. Oncotarget. 2017 Apr 04; 8(14):23851-23861. View in: Pubmed

      • Comparison of Clinical Features and Outcomes in Patients With Bilateral Versus Unilateral Adrenal Neuroblastoma. J Pediatr Hematol Oncol. 2017 03; 39(2):108-113. View in: Pubmed

      • Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017 04 20; 35(12):1341-1367. View in: Pubmed

      • Correlation of Ezrin Expression Pattern and Clinical Outcomes in Ewing Sarcoma. Sarcoma. 2017; 2017:8758623. View in: Pubmed

      • A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors. Oncotarget. 2016 Dec 20; 7(51):84736-84747. View in: Pubmed

      • Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation. Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):270-277. View in: Pubmed

      • Assessment of Chemotherapy Response in Ewing Sarcoma: Response Radiology. 2016 11; 281(2):647-649. View in: Pubmed

      • Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. J Clin Oncol. 2016 12 20; 34(36):4381-4389. View in: Pubmed

      • Somatic and Germline TP53 Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors. Clin Cancer Res. 2017 Apr 01; 23(7):1852-1861. View in: Pubmed

      • Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine. Eur J Cancer. 2016 10; 66:144-52. View in: Pubmed

      • Transcript Analysis for Internal Biodosimetry Using Peripheral Blood from Neuroblastoma Patients Treated with (131)I-mIBG, a Targeted Radionuclide. Radiat Res. 2016 09; 186(3):235-44. View in: Pubmed

      • Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience. Pediatr Blood Cancer. 2016 11; 63(11):1974-82. View in: Pubmed

      • Reply: Is Extended Sedation Necessary for Young Children Receiving High-Dose (131) I-MIBG Therapy? Pediatr Blood Cancer. 2016 10; 63(10):1868. View in: Pubmed

      • Erratum to: Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. Eur J Nucl Med Mol Imaging. 2016 Jul; 43(7):1396. View in: Pubmed

      • Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2016 10; 63(10):1771-9. View in: Pubmed

      • Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma. Clin Sarcoma Res. 2016; 6:9. View in: Pubmed

      • Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. Eur J Cancer. 2016 07; 62:9-17. View in: Pubmed

      • Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2016 May 01; 2(5):608-615. View in: Pubmed

      • Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. Cancer Genet. 2016 05; 209(5):182-94. View in: Pubmed

      • Clinical Characteristics and Outcomes of Pediatric Patients with Desmoplastic Small Round Cell Tumor. Rare Tumors. 2016 Mar 21; 8(1):6145. View in: Pubmed

      • Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome. Radiology. 2016 09; 280(3):905-15. View in: Pubmed

      • A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Clin Cancer Res. 2016 Aug 15; 22(16):4014-22. View in: Pubmed

      • Conditional Survival and Predictors of Late Death in Patients With Ewing Sarcoma. Pediatr Blood Cancer. 2016 Jun; 63(6):1091-5. View in: Pubmed

      • Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. J Clin Oncol. 2016 Apr 20; 34(12):1368-75. View in: Pubmed

      • Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. Clin Cancer Res. 2016 07 15; 22(14):3643-50. View in: Pubmed

      • Assessment of extent of surgical resection of primary high-grade osteosarcoma by treating institutions: A report from the Children's Oncology Group. J Surg Oncol. 2016 Mar; 113(4):351-4. View in: Pubmed

      • Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project. Cancer. 2016 Mar 15; 122(6):935-45. View in: Pubmed

      • Extended Sedation With Continuous Midazolam or Dexmedetomidine Infusion for Young Children Receiving 131 I-MIBG Radiopharmaceutical Therapy for Advanced Neuroblastoma. Pediatr Blood Cancer. 2016 Mar; 63(3):471-8. View in: Pubmed

      • Evaluation and Outcome of Central Nervous System Involvement in Pediatric Acute Lymphoblastic Leukemia in Dar es Salaam, Tanzania. Pediatr Blood Cancer. 2016 Mar; 63(3):458-64. View in: Pubmed

      • Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG). Pediatr Blood Cancer. 2016 Mar; 63(3):436-42. View in: Pubmed

      • Increased risk of second malignant neoplasms in adolescents and young adults with cancer. Cancer. 2016 Jan 01; 122(1):116-23. View in: Pubmed

      • Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. Eur J Nucl Med Mol Imaging. 2016 Mar; 43(3):474-481. View in: Pubmed

      • Identification of Discrete Prognostic Groups in Ewing Sarcoma. Pediatr Blood Cancer. 2016 Jan; 63(1):47-53. View in: Pubmed

      • Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG). Eur J Cancer. 2015 Nov; 51(16):2465-72. View in: Pubmed

      • Clinical features and outcomes of infants with Ewing sarcoma under 12 months of age. Pediatr Blood Cancer. 2015 Nov; 62(11):1947-51. View in: Pubmed

      • Patient-specific dosimetry using pretherapy [¹²4I]m-iodobenzylguanidine ([¹²4I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma. Mol Imaging Biol. 2015 Apr; 17(2):284-94. View in: Pubmed

      • Second malignant neoplasms among children, adolescents and young adults with Wilms tumor. Pediatr Blood Cancer. 2015 Jul; 62(7):1259-64. View in: Pubmed

      • Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2015 Jun 15; 21(12):2715-21. View in: Pubmed

      • Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma. Br J Cancer. 2015 Feb 17; 112(4):644-9. View in: Pubmed

      • Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Mar; 62(3):440-4. View in: Pubmed

      • Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium. Pediatr Blood Cancer. 2015 Jan; 62(1):45-51. View in: Pubmed

      • Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children's Oncology Group. Cancer. 2015 Feb 01; 121(3):467-75. View in: Pubmed

      • Clinical Features and Outcomes Differ between Skeletal and Extraskeletal Osteosarcoma. Sarcoma. 2014; 2014:902620. View in: Pubmed

      • Comparative evaluation of strategies for quantifying signaling pathway proteins in Ewing sarcoma. Appl Immunohistochem Mol Morphol. 2014 Sep; 22(8):593-9. View in: Pubmed

      • Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol. 2014 Oct 01; 32(28):3169-76. View in: Pubmed

      • Secondary malignant neoplasms among children, adolescents, and young adults with osteosarcoma. Cancer. 2014 Dec 15; 120(24):3987-93. View in: Pubmed

      • Pediatric cancer type predicts infection rate, need for critical care intervention, and mortality in the pediatric intensive care unit. Intensive Care Med. 2014 Oct; 40(10):1536-44. View in: Pubmed

      • Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):839-45. View in: Pubmed

      • Current treatment and outcome for childhood acute leukemia in Tanzania. Pediatr Blood Cancer. 2013 Dec; 60(12):2047-53. View in: Pubmed

      • Comparison of Latino and non-Latino patients with Ewing sarcoma. Pediatr Blood Cancer. 2014 Feb; 61(2):233-7. View in: Pubmed

      • Adverse impact of regional lymph node involvement in osteosarcoma. Eur J Cancer. 2013 Nov; 49(16):3471-6. View in: Pubmed

      • Superselective intra-arterial melphalan therapy for newly diagnosed and refractory retinoblastoma: results from a single institution. Clin Ophthalmol. 2013; 7:981-9. View in: Pubmed

      • Acute changes in blood pressure in patients with neuroblastoma treated with ¹³¹I-metaiodobenzylguanidine (MIBG). Pediatr Blood Cancer. 2013 Sep; 60(9):1424-30. View in: Pubmed

      • 131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma. Q J Nucl Med Mol Imaging. 2013 Mar; 57(1):53-65. View in: Pubmed

      • Development of anaplastic Wilms tumor and subsequent relapse in a child with diaphanospondylodysostosis. J Pediatr Hematol Oncol. 2012 Oct; 34(7):548-51. View in: Pubmed

      • 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma. Pediatr Blood Cancer. 2013 May; 60(5):879-84. View in: Pubmed

      • Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group. Int J Mol Imaging. 2012; 2012:250834. View in: Pubmed

      • Characteristics and outcomes of patients with Ewing sarcoma over 40 years of age at diagnosis. Cancer Epidemiol. 2013 Feb; 37(1):29-33. View in: Pubmed

      • Clinical features and outcomes in patients with secondary Ewing sarcoma. Pediatr Blood Cancer. 2013 Apr; 60(4):611-5. View in: Pubmed

      • Evaluation of plasma annexin V levels in children and young adults with solid tumors. Int J Biol Markers. 2012 Jul 19; 27(2):e164-6. View in: Pubmed

      • Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial. J Nucl Med. 2012 Jul; 53(7):1155-63. View in: Pubmed

      • Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer. 2012 Dec 01; 118(23):5894-902. View in: Pubmed

      • Proteinuria in metastatic pheochromocytoma is associated with an increased risk of Acute Respiratory Distress Syndrome, spontaneously or after therapy with 131I-meta-iodobenzylguanidine (131I-MIBG). Horm Metab Res. 2012 Jun; 44(7):539-42. View in: Pubmed

      • Rates and appropriateness of antimicrobial prescribing at an academic children's hospital, 2007-2010. Infect Control Hosp Epidemiol. 2012 Apr; 33(4):346-53. View in: Pubmed

      • Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. Clin Cancer Res. 2012 May 01; 18(9):2679-86. View in: Pubmed

      • Clinical features and outcomes in patients with Ewing sarcoma and regional lymph node involvement. Pediatr Blood Cancer. 2012 Oct; 59(4):617-20. View in: Pubmed

      • Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study. Cancer Chemother Pharmacol. 2012 Apr; 69(4):1021-7. View in: Pubmed

      • Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma. Pediatr Blood Cancer. 2012 Oct; 59(4):611-6. View in: Pubmed

      • Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. J Clin Oncol. 2011 Nov 20; 29(33):4358-64. View in: Pubmed

      • Evaluation of polymorphisms in EWSR1 and risk of Ewing sarcoma: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2012 Jul 15; 59(1):52-6. View in: Pubmed

      • Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clin Cancer Res. 2011 Aug 01; 17(15):5113-22. View in: Pubmed

      • Dosimetry, toxicity, and response in a phase IIa trial of no-carrier added iobenguane I-131 (nca-MIBG): A New Approach to Neuroblastoma Therapy (NANT) study. J Clin Oncol. 2011 May 20; 29(15_suppl):9512. View in: Pubmed

      • Surrogate biomarkers of antiangiogenesis in Children's Oncology Group (COG) phase I trials. J Clin Oncol. 2011 May 20; 29(15_suppl):9502. View in: Pubmed

      • Phase I study of vincristine, irinotecan, and 131I-MIBG for patients with relapsed or refractory neuroblastoma: A New Approach to Neuroblastoma Therapy (NANT) study. J Clin Oncol. 2011 May 20; 29(15_suppl):9513. View in: Pubmed

      • Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. Cancer Lett. 2011 Jul 28; 306(2):223-9. View in: Pubmed

      • Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. Clin Cancer Res. 2011 Apr 15; 17(8):2339-49. View in: Pubmed

      • Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults. Cancer. 2011 Sep 15; 117(18):4286-93. View in: Pubmed

      • Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma. Pediatr Blood Cancer. 2012 Feb; 58(2):181-4. View in: Pubmed

      • Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. Cancer. 2011 Jul 01; 117(13):3027-32. View in: Pubmed

      • Racial differences in the incidence of mesenchymal tumors associated with EWSR1 translocation. Cancer Epidemiol Biomarkers Prev. 2011 Mar; 20(3):449-53. View in: Pubmed

      • Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer. 2010 Aug; 55(2):254-9. View in: Pubmed

      • Osteosarcoma in children 5 years of age or younger at initial diagnosis. Pediatr Blood Cancer. 2010 Aug; 55(2):285-9. View in: Pubmed

      • p53+/mdm2- atypical lipomatous tumor/well-differentiated liposarcoma in young children: an early expression of Li-Fraumeni syndrome. Pediatr Dev Pathol. 2010 May-Jun; 13(3):218-24. View in: Pubmed

      • Ethnic and racial differences in patients with Ewing sarcoma. Cancer. 2010 Feb 15; 116(4):983-8. View in: Pubmed

      • Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data. Cancer. 2010 Feb 01; 116(3):749-57. View in: Pubmed

      • Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow. Pediatr Blood Cancer. 2010 Jan; 54(1):13-8. View in: Pubmed

      • Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumors. J Clin Oncol. 2009 May 20; 27(15_suppl):10502. View in: Pubmed

      • Significance of tumor biology compared to metastatic pattern (INSS 4 versus 4s) and age for prognosis of neuroblastoma less than 18 months of age. J Clin Oncol. 2009 May 20; 27(15_suppl):10010. View in: Pubmed

      • Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapy. Int J Radiat Oncol Biol Phys. 2009 Sep 01; 75(1):177-82. View in: Pubmed

      • Chemotherapy: The role of ifosfamide and etoposide in Ewing sarcoma. Nat Rev Clin Oncol. 2009 May; 6(5):251-3. View in: Pubmed

      • Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009 Mar; 52(3):324-7. View in: Pubmed

      • Ototoxicity in children treated for osteosarcoma. Pediatr Blood Cancer. 2009 Mar; 52(3):387-91. View in: Pubmed

      • Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging. 2008 Dec; 52(4):403-18. View in: Pubmed

      • Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2008 Nov; 51(5):589-92. View in: Pubmed

      • Late recurrence of ewing sarcoma during pregnancy: a report of 2 cases. J Pediatr Hematol Oncol. 2008 Sep; 30(9):716-8. View in: Pubmed

      • Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol. 2008 Aug; 35 Suppl 1:S35-48. View in: Pubmed

      • Early lymphocyte recovery in Ewing sarcoma. J Pediatr Hematol Oncol. 2007 May; 29(5):351-2. View in: Pubmed

      • Desmoplastic small round cell tumor of the kidney in childhood. Am J Surg Pathol. 2007 Apr; 31(4):576-84. View in: Pubmed

      • Markers of angiogenesis and clinical features in patients with sarcoma. Cancer. 2007 Mar 01; 109(5):813-9. View in: Pubmed

      • Combined effects of granulocyte colony stimulating factor and radiation. Clin Nucl Med. 2007 Jan; 32(1):39-41. View in: Pubmed

      • Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol. 2004 Jun 15; 22(12):2452-60. View in: Pubmed

      • Pediatric acute blastic natural killer cell leukemia. Leuk Lymphoma. 2002 Apr; 43(4):901-6. View in: Pubmed

      • Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 1999 May-Jun; 21(3):181-9. View in: Pubmed

      Locations

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Boston, MA 02215
      Get Directions

      Dana-Farber Cancer Institute

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Boston, MA 02215
      Get Direction
      42.3374, -71.1082

      Discovery and Insights